VM 206

Drug Profile

VM 206

Alternative Names: VM-206; VM-206RY; VM206DNA

Latest Information Update: 08 Apr 2016

Price : $50

At a glance

  • Originator ViroMed Co Ltd
  • Developer Reyon Pharmaceutical; ViroMed
  • Class Cancer vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 22 Oct 2013 Reyon Pharmaceutical completes a phase I trial in Breast cancer in South Korea (NCT01895491)
  • 03 Oct 2011 RecipharmCobra Biologics is now called Cobra Biologics
  • 31 Mar 2011 Phase-I clinical trials in Breast cancer (second-line therapy or greater) in South Korea (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top